This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
Subjects are identified based on whether they received tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or who did not elect to enroll in long-term extension studies. Subjects are pre-identified
Study Type
OBSERVATIONAL
Enrollment
83
Subjects who previously took 15 mg BID or 30 mg BID
Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
Number of Participants With Clinical Outcome of Post Transplant Lymphoproliferative Disease (PTLD)
All lymphoproliferative disorders diagnosed locally as PTLD based on histopathology were reported.
Time frame: Baseline through Month 12
Number of Participants With Central Nervous System (CNS) Infection
Participants with CNS infection involving the brain or spinal cord, within 12 months after the last dose of tofacitinib were reported.
Time frame: Baseline through Month 12
Number of Participants With Graft Failure
Graft failure which occurred within 12 months after the last dose of tofacitinib was reported. Graft failure was defined as graft nephrectomy, re-transplantation, or return to dialysis for greater than or equal to (\>=) 6 consecutive weeks.
Time frame: Baseline through Month 12
Number of Participants Who Died
Time frame: Baseline through Month 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Palo Alto, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Stanford, California, United States
Pfizer Investigational Site
Aurora, Colorado, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
...and 33 more locations